GlassScriptPhysician profile
Nathan Thomas Hill
NPI 1801207857
$9,072.06
in general payments reported to CMS, 2019-2025
26 companies · $882 in 2025
The $882 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $5,443 · 2021: $296 · 2022: $83.64 · 2023: $784 · 2024: $1,196 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,863.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $5,442.61 | 2020 | |
| Glaxosmithkline, LLC. | $645.92 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $532.96 | 2021-2025 | Ofev, Jascayd |
| Olympus Corporation | $345.26 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $281.63 | 2023-2025 | Airsupra, Breztri, Fasenra |
| Genzyme Corporation | $263.56 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $192.60 | 2023-2024 | Acthar |
| Grifols USA, LLC | $188.53 | 2021-2024 | Prolastin-C Liquid |
| Stryker Corporation | $183.93 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Mylan Specialty L.P. | $164.22 | 2021-2024 | Yupelri |
| Intuitive Surgical, INC. | $134.45 | 2024 | |
| Vifor Pharma, INC. | $90.88 | 2024-2025 | Zemaira, Veltassa |
| Regeneron Healthcare Solutions, INC. | $90.77 | 2024-2025 | Dupixent |
| Verona Pharma, INC. | $73.53 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $58.82 | 2023-2025 | Glassia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $58.45 | 2021-2023 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $50.80 | 2021-2024 | Opsumit, Uptravi |
| Viatris Specialty LLC | $47.74 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $43.55 | 2023 | Dificid, Recarbrio, Zerbaxa |
| Baxter Healthcare | $43.16 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Pinnacle Biologics, INC | $41.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.31 | 2021-2023 | Xarelto |
| Paratek Pharmaceuticals, INC. | $23.13 | 2023 | Nuzyra |
| Philips North America LLC | $21.36 | 2024 | (Ak6) Vest Therapy |
| Inogen, INC. | $14.98 | 2024 | |
| Boston Scientific Corporation | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.